Anophthalmia and Microphthalmia Market Research Report- Global Forecast till 2027

Anophthalmia And Microphthalmia Market Information: By Diagnosis (CT Scan, MR Scan, Chromosome Analysis, Ultrasonography), By Treatment (Surgical), End User (Hospitals & Clinics, Research Centers) - Global Forecast Till 2027

ID: MRFR/Pharma/3302-HCR | February 2021 | Region: Global | 135 pages

Anophthalmia and Microphthalmia Market Scenario


Anophthalmia and microphthalmia mean the absence of an eye and the presence of a small eye within the orbit. Anophthalmia and microphthalmia are interchangeable. Whereas, microphthalmia is a disorder in which one or both eyes are abnormally small, while anophthalmia is the absence of one or both eyes. Anophthalmia and microphthalmia mostly occur during pregnancy. However, anophthalmia and microphthalmia often result in blindness or limited vision. It is a rare disorder and the severe case has treatment unavailability.


The major causes may include genetic mutations and abnormal chromosomes. Exposure to X-rays, chemicals, drugs, pesticides, toxins, radiation, or viruses, increases the risk of anophthalmia and microphthalmia. Anophthalmia and microphthalmia lead to optic disc dysplasia as well as non-ocular features like mental retardation, neurological abnormalities, and facial dysmorphisms.


The anophthalmia and microphthalmia market growth is majorly attributed to the increasing prevalence of the genetic disorders and eye-related disorders. Moreover, the increasing mental retardation, neurological abnormalities are expected to drive the Anophthalmia and Microphthalmia Market growth over the assessment period.


According to the World Health Organization (WHO), an estimated 253 million people live with vision impairment 36 million are blind and 217 million have moderate to severe vision impairment worldwide. An estimated 19 million children (below age 15) are vision impaired.


Furthermore, According to the WHO estimates, neurological abnormalities are responsible for 4.5%-11% of all illnesses including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.


However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.


The anophthalmia and microphthalmia market is expected to grow at a CAGR of ~5.8 % during the forecast period 2017-2023. 


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers

  • Potential Investors


Figure: Anophthalmia and Microphthalmia Market, By Region Market Share, 2016 (%) Anophthalmia and Microphthalmia Market

Sources: Annual reports, Press release, White paper, Company presentation


Segmentations


The anophthalmia and microphthalmia market is segmented on the basis by diagnosis, by treatment, and by the end user.


On the basis of the diagnosis, it is segmented into CT scan, MR scan, chromosome analysis, ultrasonography, and others.  


On the basis of treatment, it is segmented into surgery and others.


On the basis of the end user, it is segmented into hospitals & clinics, research centers, and others.


Regional Analysis


The Americas dominate the anophthalmia and microphthalmia market owing to well-developed technology, increased patient pool with genetic disorders, high health care spending, and government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the Anophthalmia and Microphthalmia Market in this region.


Europe holds the second position in the anophthalmia and microphthalmia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period.


Asia Pacific is the fastest growing anophthalmia and microphthalmia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the growth of the anophthalmia and microphthalmia market in the region.


On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment. 


Key Players


Some of key the players in the Anophthalmia and Microphthalmia Market are Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others.


Research Methodology Anophthalmia and Microphthalmia Market-


Sources: Annual reports, Press release, White paper, and Company presentation



Speak to Analyst Ask for Customization

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Anophthalmia and Microphthalmia Market, by Diagnosis

6.1 Introduction

6.2 CT scan

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 MR scan

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Chromosome analysis

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 Ultrasonography

6.4.1 Market Estimates & Forecast, 2020-2027

7. Global Anophthalmia and Microphthalmia Market, by Treatment

7.1 Introduction

7.2 Surgery

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Others

7.3.1 Market Estimates & Forecast, 2020-2027

8. Global Anophthalmia and Microphthalmia Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Research centers

8.3.1 Market Estimates & Forecast, 2020-2027

9. Global Anophthalmia and Microphthalmia Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 U.K.

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Bristol-Myers Squibb Company

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 NUSAPURE

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Pfizer Inc

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 ALLERGAN

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Aerie Pharmaceuticals, Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Valeant Pharmaceuticals International, Inc

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Regeneron Pharmaceuticals, Inc

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES

Table 1 Anophthalmia and Microphthalmia Industry Synopsis, 2020-2027

Table 2 Global Anophthalmia and Microphthalmia Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Anophthalmia and Microphthalmia Market by Region, 2020-2027, (USD Million)

Table 4 Global Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 6 Global Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)

Table 7 North America Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)

Table 10 U.S. Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 11 US Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 12 US Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)

Table 13 Canada Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)

Table 16 South America Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)

Table 19 Europe Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)

Table 22 Western Europe Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)

Table 25 Eastern Europe Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)

Table 28 Asia Pacific Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia Pacific Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)

Table 31 Middle East & Africa Anophthalmia and Microphthalmia Market by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa Anophthalmia and Microphthalmia Market by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Anophthalmia and Microphthalmia Market by End Users, 2020-2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Anophthalmia and Microphthalmia Market

Figure 3 Segmentation Market Dynamics for Anophthalmia and Microphthalmia Market

Figure 4 Global Anophthalmia and Microphthalmia Market Share, by Diagnosis 2020

Figure 5 Global Anophthalmia and Microphthalmia Market Share, by Treatment 2020

Figure 6 Global Anophthalmia and Microphthalmia Market Share, by End Users, 2020

Figure 7 Global Anophthalmia and Microphthalmia Market Share, by Region, 2020

Figure 8 North America Anophthalmia and Microphthalmia Market Share, by Country, 2020

Figure 9 Europe Anophthalmia and Microphthalmia Market Share, by Country, 2020

Figure 10 Asia Pacific Anophthalmia and Microphthalmia Market Share, by Country, 2020

Figure 11 Middle East & Africa Anophthalmia and Microphthalmia Market Share, by Country, 2020

Figure 12 Global Anophthalmia and Microphthalmia Market: Company Share Analysis, 2020 (%)

Figure 13 Bristol-Myers Squibb Company: Key Financials

Figure 14 Bristol-Myers Squibb Company: Segmental Revenue

Figure 16 Bristol-Myers Squibb Company: Geographical Revenue

Figure 17 NUSAPURE: Key Financials

Figure 18 NUSAPURE: Segmental Revenue

Figure 19 NUSAPURE: Geographical Revenue

Figure 20 Pfizer Inc: Key Financials

Figure 21 Pfizer Inc: Segmental Revenue

Figure 22 Pfizer Inc: Geographical Revenue

Figure 23 ALLERGAN: Key Financials

Figure 24 ALLERGAN: Segmental Revenue

Figure 25 ALLERGAN: Geographical Revenue

Figure 26 Aerie Pharmaceuticals, Inc: Key Financials

Figure 27 Aerie Pharmaceuticals, Inc.: Segmental Revenue

Figure 28 Aerie Pharmaceuticals, Inc.: Geographical Revenue

Figure 29 Valeant Pharmaceuticals International, Inc: Key Financials

Figure 30 Valeant Pharmaceuticals International, Inc: Segmental Revenue

Figure 31 Valeant Pharmaceuticals International, Inc: Geographical Revenue

Figure 32 Regeneron Pharmaceuticals, Inc: Key Financials

Figure 33 Regeneron Pharmaceuticals, Inc: Segmental Revenue

Figure 34 Regeneron Pharmaceuticals, Inc: Geographical Revenue